Cipla Q3 Results: Cipla reported a 57% YoY drop in net profit to Rs 676 crore, impacted by lower gRevlimid sales in North America. Despite this, the company’s One India business saw double-digit growth in branded prescriptions, and upcoming launches are expected to offset future revenue declines.
